- Price
- $12.92
- Day
- +1.73%
- Mkt Cap
- $1.67B
- 52W Range
- $12.47 – $28.23
- Volume
- 1.04M
- Beta
- 0.50
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.
Read full article
WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Wednesday, September 23, 2026, 9:40 a.m.
Read full article
Atlas Venture Life Science Advisors LLC acquired a new position in shares of Kailera Therapeutics, Inc. (NASDAQ: KLRA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,171,282 shares of the company's stock, valued at approximately $113,923,000. Kailera Therapeutics comprises 12.9%
Read full article